Navigation Links
* Quick & Easy Conditional Knock Out Kit - FRT from Gene Bridges GmbH

Products* Quick & Easy Conditional Knock Out Kit - FRT from Gene Bridges GmbH
Company Gene Bridges GmbH
Item * Quick & Easy Conditional Knock Out Kit - FRT
Price 
Description This kit is designed for the fast and simple integration of FRT-sites into large vector plasmids at any position (for the generation of transgenic mouse models). The included FRT-PGK-gb2-neo-FRT cassette is designed to allow neomycin / kanamycin selection in prokaryotic and eukaryotic cells. It combines a prokaryotic promoter (gb2) for expression of kanamycin resistance in E.coli with a eukaryotic promoter (PGK) for expression of neomycin resistance in mammalian cells. The included pCI-FLPe expression plasmid codes for an improved Flp recombinase which shows a four to tenfold higher recombinational activity compared to the wildtype Flp enzyme at temperatures between 37C (optimal growth temperature for E.coli) and 40C (mouse body temperature). This kit can also be used to work on bacterial artificial chromosomes (BACs). The generation of targeting constructs is achieved utilizing the high Red/ET efficiency plus the convenient removal of the Red/ET Recombineering protein expression plasmid pRedET after recombination.
The kit is available to academic researchers. Commercial organizations require a sub-license from Gene Bridges.

  • Additional Specifications: Also available as as service.
Info Gene Bridges GmbH
Commercial Centre
Im Neuenheimer Feld 584
69120 Heidekberg, Germany
Customer Service: +49 (0)6221 13708 10
Fax Number: +49 (0)6221 13708 29
Web Site: http://www.Genebridges.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. * Quick & Easy Conditional Knock Out Kit - loxP from Gene Bridges GmbH
2. QuickLane Individual Sample Sequencing from Agencourt Bioscience
3. * Quick & Easy E. coli Gene Deletion Kit from Gene Bridges GmbH
4. TNT® T7 Quick Coupled Transcription/Translation System from Promega
5. TargeTron Gene Knockout System from Sigma-Aldrich
6. FRT flanked, Pro and Euk. Neomycin Selection Cassette (FRT-PGK-gb2-neo-FRT) from Gene Bridges GmbH
7. loxP flanked, Pro and Euk. Neomycin Selection Cassette (loxP-PGK-gb2-neo-loxP) from Gene Bridges GmbH
8. FRT flanked, Pro and Euk. Neomycin Selection Cassette plus loxP site(FRT-PGK-gb2-neo-FRT-loxP) from Gene Bridges GmbH
9. loxP flanked Chloramphenicol Selection Cassette (loxP-cm-loxP) from Gene Bridges GmbH
10. FRT flanked Ampicillin Selection Cassette (FRT-amp-FRT) from Gene Bridges GmbH
11. loxP flanked Ampicillin Selection Cassette (loxP-amp-loxP) from Gene Bridges GmbH
(Date:7/30/2014)... Press Limited today announced an across-the-board increase in ... The 2013 InCites Journal Citation Reports (Thomson Reuters, ... Biochemical Journal , Essays in Biochemistry , ... Reports all received increases in their Impact ... Society and published by Portland Press Limited. , ...
(Date:7/30/2014)... State University,s College of Engineering recently received a ... the project, "Nanoparticle-directed synthesis of organic nanorods." ... is the creation and utilization of functional materials, ... A major bottleneck in scaling up nanotechnology is ... functional materials into one device. A research team ...
(Date:7/30/2014)... Embryonic stem cells can develop into a multitude of cells ... development into the specific types of mature cells that make ... , One key seems to be long chains of sugars ... Godula,s group at the University of California, San Diego, has ... sugars, but can be more easily manipulated to direct the ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... New South Wales (UNSW) researchers have announced they are developing ... to treat a diverse range of health problems, from inflammation ... is published in the July issue of Nature Biotechnology. ... age-related macular degeneration (AMD) and diabetic retinopathy are likely to ...
... Physicians and surgeons will someday monitor a patient's blood ... thanks to research being conducted by a Cornell University ... new technology is being developed by Edwin Kan, associate ... Transonic Systems of Ithaca. Kan performed much of his ...
... factors that would explain the different life expectancies of ... universal, according to University of Michigan researchers. , "Women ... difference in lifespan has been recognized since at least ... scientist in the U-M School of Public Health and ...
Cached Biology News:'Molecular assassin' targets disease gene 2Researchers to develop ultra-miniature implantable sensors to measure blood flow 2Evolutionary forces explain why women live longer than men 2
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... NYSE: SNY) today announced that the Companies intend to ... pediatric disease priority review voucher in connection with the ... review voucher entitles the holder to designate a BLA ... review from the filing date instead of the standard ...
(Date:7/30/2014)... 30, 2014  Replikins Ltd. today released new data ... virus. Before the current outbreaks, the mean Ebola Reston ... acids) between 1995 and 2002 was 1.1; the mean ... and sixteen-fold in 2013, thus predicting the current outbreaks ... has been shown to be able to predict outbreaks ...
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Read complete report with ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3